- Home
- MPA vs MYO Comparison
MPA vs MYO Comparison
Compare MPA & MYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPA
- MYO
- Stock Information
- Founded
- MPA 1992
- MYO 2004
- Country
- MPA United States
- MYO United States
- Employees
- MPA N/A
- MYO N/A
- Industry
- MPA Finance Companies
- MYO Industrial Specialties
- Sector
- MPA Finance
- MYO Health Care
- Exchange
- MPA Nasdaq
- MYO Nasdaq
- Market Cap
- MPA 139.5M
- MYO 153.0M
- IPO Year
- MPA N/A
- MYO 2017
- Fundamental
- Price
- MPA $10.76
- MYO $1.00
- Analyst Decision
- MPA
- MYO Strong Buy
- Analyst Count
- MPA 0
- MYO 3
- Target Price
- MPA N/A
- MYO $8.17
- AVG Volume (30 Days)
- MPA 25.2K
- MYO 1.3M
- Earning Date
- MPA 01-01-0001
- MYO 08-11-2025
- Dividend Yield
- MPA 3.83%
- MYO N/A
- EPS Growth
- MPA N/A
- MYO N/A
- EPS
- MPA N/A
- MYO N/A
- Revenue
- MPA N/A
- MYO $40,760,091.00
- Revenue This Year
- MPA N/A
- MYO $52.68
- Revenue Next Year
- MPA N/A
- MYO $28.33
- P/E Ratio
- MPA N/A
- MYO N/A
- Revenue Growth
- MPA N/A
- MYO 93.08
- 52 Week Low
- MPA $9.87
- MYO $0.92
- 52 Week High
- MPA $12.21
- MYO $7.17
- Technical
- Relative Strength Index (RSI)
- MPA 52.25
- MYO 16.39
- Support Level
- MPA $10.75
- MYO $0.95
- Resistance Level
- MPA $10.92
- MYO $1.16
- Average True Range (ATR)
- MPA 0.08
- MYO 0.12
- MACD
- MPA 0.01
- MYO -0.09
- Stochastic Oscillator
- MPA 57.87
- MYO 6.47
About MPA Blackrock MuniYield Pennsylvania Quality Fund
Blackrock Muniyield Pennsylvania Quality Fund is a closed-end fund with investment objective is to provide shareholders with as high a level of current income exempt from U.S. federal and Pennsylvania income taxes as is consistent with its investment policies and prudent investment management.
About MYO Myomo Inc.
Myomo Inc is a wearable medical robotics company that develops, designs, and produces myoelectric orthotics for people with neuromuscular disorders. The MyoPro myoelectric upper limb orthosis product is registered with the Food and Drug Administration as a Class II medical device. The company provides the devices to patients and bills their insurance companies directly, sometimes utilizing the clinical services of orthotics and prosthetics providers for which a fee is paid. The company sells the product to orthotics and prosthetics providers around the world and the Veterans Health Administration (VA).